Inclusion Criteria:

1. Male or female,18 years of age or older.

2. Chemotherapy-naive patients with metastatic or unresectable non-small cell lung
cancer.

3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

4. Normal left ventricular ejection fraction (LVEF).

5. At least one unidimensionally measurable lesion with a diameter > 10 mm using CT
scan.

6. Life expectancy greater than 3 months.

7. Neutrophils 1,500/L, Platelets 100,000/L, AST/ALT 2.5 ULN (< 5 ULN if liver
metastases), Alkaline phosphatase 2.5 ULN, Serum bilirubin 1.5 ULN, Serum Creatinine
1.5 ULN.

8. Urine dipstick of proteinuria <2+. Patients discovered to have 2+ proteinuria on
dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must
demonstrate 1g of protein/24 hr.

9. Patients in this study should avoid having child. Women of childbearing potential
must have a negative serum pregnancy test done 1 week prior to the administration of
the study drug. She and her partner should prevent pregnancy (oral contraceptives,
intrauterine contraceptive device, barrier method of contraception in conjunction
with spermicidal jelly or surgically sterile) up to at least 6 months after last
treatment completion or the last drug dose, whatever happens first.

10. Signed written informed consent according to ICH/GCP and the local regulations
(approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC])
will be obtained prior to any study specific screening procedures.

11. Patient must be able to comply with the protocol.

Exclusion Criteria:

1. Poor condition and inappropriate situation to enter this study, which could be
determined by the principle investigator or in-charge attending physician.

2. Uncontrolled hypertension (systolic blood pressure > 160 mm Hg, diastolic blood
pressure > 90 mm Hg).

3. Prior exposure to VEGF inhibitors.

4. Major surgical procedure, open biopsy or significant traumatic injury within 28 days
prior to Day 0 (Patients must have recovered from any major surgery), or anticipation
of need for major surgical procedure during the course of the study.

5. Planned radiotherapy for underlying disease (prior completed radiotherapy treatment
allowed).

6. Clinical or radiological evidence of CNS metastases.

7. Serious non-healing wound or ulcer.

8. Evidence of bleeding diathesis or coagulopathy.

9. Clinically significant (i.e. active) cardiovascular disease for example
cerebrovascular accidents (≤ 6 months), myocardial infarction (≤ 6 months), unstable
angina, New York Heart Association (NYHA) grade II or greater congestive heart
failure, serious cardiac arrhythmia requiring medication. Stroke in the preceding six
months.

10. Current or recent (within 10 days prior to study treatment start) ongoing treatment
with anticoagulants for therapeutic purposes i.e. except for anticoagulation for
maintenance of potency of permanent indwelling IV catheters.

11. Evidence of other disease, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition
that contraindicates use of an investigational drug or patient at high risk from
treatment complications.

12. Ongoing treatment with large dose aspirin (> 325 mg/day) or other medications known
to predispose to gastrointestinal ulceration (Continuous using NSAIDs).

13. Pregnancy (positive serum pregnancy test) and lactation.

14. Any other serious or uncontrolled illness which, in the opinion of the investigator,
makes it undesirable for the patient to enter the trial.